Grifols (NASDAQ:GRFS) Now Covered by Morgan Stanley

Equities research analysts at Morgan Stanley assumed coverage on shares of Grifols (NASDAQ:GRFS) in a research report issued on Wednesday. The brokerage set an “overweight” rating on the biotechnology company’s stock.

Separately, Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Price Performance

Shares of NASDAQ:GRFS traded down $0.08 during trading on Wednesday, reaching $7.12. The stock had a trading volume of 262,096 shares, compared to its average volume of 782,943. Grifols has a 52 week low of $5.30 and a 52 week high of $9.96. The business’s 50-day moving average price is $7.38 and its 200 day moving average price is $8.10. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Institutional Investors Weigh In On Grifols

Institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC bought a new position in Grifols during the second quarter worth about $89,000. GAMMA Investing LLC grew its holdings in Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 1,135 shares during the period. Creative Planning grew its holdings in Grifols by 26.4% during the third quarter. Creative Planning now owns 17,319 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 3,614 shares during the period. NBC Securities Inc. increased its stake in Grifols by 2.8% in the third quarter. NBC Securities Inc. now owns 52,181 shares of the biotechnology company’s stock valued at $463,000 after purchasing an additional 1,433 shares in the last quarter. Finally, Signaturefd LLC raised its holdings in Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 2,153 shares during the period.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.